Keywords: AstraZeneca Rigel Pharma, Fostamatinib, Rheumatoid arthritis, Licensing

AstraZeneca in deal for Rigel RA drug that could cost up to $1.25 billion

Article | 16 February 2010

Print This

In what looks like ranking among the biggest drug licensing deals, Anglo-Swedish major AstraZeneca has entered into an exclusive worldwide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in